PrecivityAD2 as an Adjunct to a 2026 Alzheimer’s Assessment: Result Interpretation Questions for People With Mild Cognitive Impairment

Why a "likely positive" PrecivityAD2 result needs a second test, not a second opinion on the same number.

Why a "likely positive" PrecivityAD2 result needs a second test, not a second opinion on the same number.

Why a PrecivityAD2 result's three tiers — positive, likely positive, and negative — carry very different odds of being right.

Caregivers missed the comment deadline but still have a clear path to track the next decade-long Alzheimer's plan before it's finalized.

Why the plan guiding Alzheimer's caregiver support just missed its own 2025 deadline, and what federal programs still work right now.

The new at-home Leqembi start changes how the drug is given, not who qualifies or how closely ARIA risk gets monitored.

A breakdown of what PROTECT-Cog actually tests, who qualifies, and why results won't arrive for years.

A $5,000 tau PET scan and a $200 blood test now track similarly for MCI progression risk — here's when each one actually applies.

Tauklarify adds a second FDA-cleared tau PET option alongside amyloid PET — here's what each scan tells an MCI patient and what it doesn't.

A side-by-side look at what Tauklarify's accuracy data and rollout gaps mean for patients deciding on tau PET imaging now.

Two FDA-approved tau PET tracers now exist for Alzheimer's evaluation, with head-to-head trial data showing how their scan results compare.
HelpDementia.com
Dementia, Alzheimer's, Caregiving & Healthy Aging Guidance
© 2026 HelpDementia.com. All rights reserved.
Educational information only. It is not medical advice and does not replace care from a qualified clinician.